The stock of Achilles Therapeutics Plc ADR (ACHL) has gone up by 22.47% for the week, with a 21.92% rise in the past month and a 39.00% rise in the past quarter. The volatility ratio for the week is 3.68%, and the volatility levels for the past 30 days are 3.59% for ACHL. The simple moving average for the past 20 days is 19.48% for ACHL’s stock, with a 49.36% simple moving average for the past 200 days.
Is It Worth Investing in Achilles Therapeutics Plc ADR (NASDAQ: ACHL) Right Now?
Company’s 36-month beta value is 1.31.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ACHL is 37.95M, and currently, short sellers hold a 0.32% ratio of that floaft. The average trading volume of ACHL on February 04, 2025 was 175.74K shares.
ACHL) stock’s latest price update
Achilles Therapeutics Plc ADR (NASDAQ: ACHL) has experienced a rise in its stock price by 24.11 compared to its previous closing price of 1.12. However, the company has seen a gain of 22.47% in its stock price over the last five trading days. globenewswire.com reported 2024-12-24 that – Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction –
Analysts’ Opinion of ACHL
Many brokerage firms have already submitted their reports for ACHL stocks, with Piper Sandler repeating the rating for ACHL by listing it as a “Neutral.” The predicted price for ACHL in the upcoming period, according to Piper Sandler is $2 based on the research report published on April 05, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ACHL reach a price target of $25. The rating they have provided for ACHL stocks is “Overweight” according to the report published on April 26th, 2021.
Oppenheimer gave a rating of “Outperform” to ACHL, setting the target price at $23 in the report published on April 26th of the previous year.
ACHL Trading at 26.27% from the 50-Day Moving Average
After a stumble in the market that brought ACHL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.02% of loss for the given period.
Volatility was left at 3.59%, however, over the last 30 days, the volatility rate increased by 3.68%, as shares surge +20.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.33% upper at present.
During the last 5 trading sessions, ACHL rose by +23.35%, which changed the moving average for the period of 200-days by +71.88% in comparison to the 20-day moving average, which settled at $1.1639. In addition, Achilles Therapeutics Plc ADR saw 21.93% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ACHL
The total capital return value is set at -0.69. Equity return is now at value -52.41, with -45.13 for asset returns.
Based on Achilles Therapeutics Plc ADR (ACHL), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -8.47.
Currently, EBITDA for the company is -70.44 million with net debt to EBITDA at 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.04.
Conclusion
In a nutshell, Achilles Therapeutics Plc ADR (ACHL) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
